Table 3.
Best tumor response in all patients and subgroups.
| Total n=91 |
BCLC stage A n=9 |
BCLC stage B n=30 |
BCLC stage C n=52 |
|
|---|---|---|---|---|
| CR | 7 (7.7%) | 2 (22.2%) | 1 (3.3%) | 4 (7.7%) |
| PR | 46 (50.5%) | 6 (66.7%) | 14 (46.7%) | 26 (50.0%) |
| SD | 21 (23.1%) | 1 (11.1%) | 6 (20.0%) | 10 (19.2%) |
| PD | 17 (18.7%) | 0 (0) | 9 (30.0%) | 12 (23.1%) |
| ORR* | 53 (58.2%) | 8 (88.9%) | 15 (50.0%) | 30 (57.7%) |
| DCR | 74 (81.3%) | 9 (100%) | 21 (70.0%) | 40 (76.9%) |
| Median OS (m) | 17 | / | 17 | 17 |
| Median PFS (m) | 10 | 23.5 | 11 | 10 |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; OS, overall survival; PFS, progression-free survival.
*The P value of ORR between BCLC stage A, B and C was 0.084; between BCLC stage A and B was 0.09; between BCLC stage A and C was 0.158; between BCLC stage B and C was 0.500.